|Bid||49.89 x 800|
|Ask||0.00 x 800|
|Day's Range||49.21 - 49.71|
|52 Week Range||40.00 - 51.84|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||25.57|
|Forward Dividend & Yield||1.74 (3.51%)|
|Ex-Dividend Date||May 05, 2019|
|1y Target Est||55.25|
Sanofi (NASDAQ: SNY; EURONEXT: SAN) announced today the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash.
(Bloomberg Opinion) -- Drugmakers have made significant scientific advances in recent years. Unfortunately, their ability to combat potential pandemics isn't included.Driven in part by high prices and an easier path to profit, pharmaceutical companies have increasingly focused on medicines targeting cancer and rare diseases, and they are often amply rewarded by investors for doing so. That's helped lead to important new drugs and a notable drop in American cancer deaths. But, as I have noted, those efforts can come at the expense of vital but less lucrative work in the service of public health.The recent outbreak of a deadly respiratory illness in China has reminded the world of the threat of new diseases and their potential for spreading globally. As part of efforts to contain the virus, China this week halted travel out of Wuhan and neighboring municipalities, while the World Health Organization said it will decide Thursday on whether to declare the outbreak a public health emergency of international concern as the death toll climbed. The current crisis may abate, but the threat of pandemics won’t. It's past time to take steps to make sure that the world has the scientific and medical firepower it will need — and large drugmakers could play a much bigger part than they are now.Just 20 pharmaceutical companies spent more than $2 billion on research and development over the past 12 months, and they control the majority of the money spent on formulating new medicines. After years of consolidation, only four have major vaccine units. Smaller biotechnology firms are entering this area and could bring exciting new approaches to bear, but they are less proven. While a virus is behind the latest outbreak, drug-resistant bacteria may be an even scarier long-term threat. Novartis AG and Sanofi, among others, have stepped back from the development of new antibacterials. There’s not enough new research, and as big companies disengage, antibiotic infrastructure could get weaker. That may lead to access and availability issues for even today's aging options.If a company did develop a new class of antibiotics, doctors would use them as little as possible to avoid creating resistance. And vaccines for diseases that pop up sporadically aren't sure bets even to recover development costs. So there are significant disincentives for going big in these medicines as opposed to other more lucrative areas.Publicly funded research can fill some gaps, but can't do it all. The Centers for Disease Control and Prevention spent about $500 million on programs aimed at emerging infectious diseases last year, but is battling funding cuts. The National Institutes for Health sent about $5.5 billion to the institute that focuses on infectious diseases in 2019. Those funds also have to cover research into allergic, immunologic, and inflammatory conditions; only a portion goes directly to research targeting potential future pandemics, and it’s split between many labs and projects. Public research also rarely turns into actual medicine without a pharmaceutical company's expertise. Merck & Co.’s Ebola vaccine, one of just a few recent success stories, originated in a publicly funded Canadian lab. The vaccine had looked promising for more than a decade, but it took years and multiple outbreaks for it to get developed and approved last year. The vaccine is a success, but not exactly a ringing endorsement for an ecosystem where fewer drugmakers have the ability or will to do this essential work. The possibility for blockbuster sales motivates large drugmakers; little else moves the needle. The revenue potential for many infectious disease drugs is likely to remain limited, so other serious incentives are required. Whether it’s cash prizes that actually matter to companies that generate billions in revenue, or significant tax breaks, or extra market exclusivity for bestselling medicines, whatever it takes to get companies to re-engage is worth trying out. Just financing individual projects isn't enough; drugmakers need to feel reassured enough to rebuild the ability to develop and produce these sorts of medicines at scale.At the same time, public efforts need more funding in order to make the basic breakthroughs that drugmakers can capitalize on. Researchers need an easier path to alliances with public health organizations and private companies that will see their best efforts make it to the market in a timely fashion. Cancer and heart disease kill more Americans than infectious diseases in an average year. It could take take just one epidemic to change that, and we need to build a system that’s up to the challenge.To contact the author of this story: Max Nisen at firstname.lastname@example.orgTo contact the editor responsible for this story: Beth Williams at email@example.comThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Drug companies are not making progress against the spread of antibiotic resistance at a scale and speed great enough to tackle the global health threat posed by superbugs, a key benchmark analysis found on Tuesday. The findings of a second Antimicrobial Resistance (AMR) Benchmark report showed that while a few pharmaceutical companies are expanding their efforts, change is not happening at the scale needed to radically impact the problem. In India, drug resistance exceeds 70% for many widespread bacteria, the AMR report said.
The Redwood City company raised $226 million in three venture rounds after its formation five years ago by Third Rock Ventures.
Presidential candidates have the drug industry in their sights, but executives and investors say they are ready.
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
Heading into the new year, only one word matters for the biotech stocks: buyout.Already, we've seen a fury of activity this past year, as many of the larger pharmaceutical and biotech giants look to plug holes in their aging pipelines. This activity accelerated at the end of the end, with Novartis (NYSE:NVS), Merck (NYSE:MRK) and Sanofi (NASDAQ:SNY) all making big blockbuster buys over the last month or so.And, the buys could continue into the new year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor one thing, many of the big biotech stocks are flushed with cash. Thanks to the tax cuts of 2017, repatriation of cash and continued sales of blockbuster drugs, many of the biggest biotech stocks are holding billions on their balance sheets. Meanwhile, pipelines and approvals of new drugs are starting to dry up. According to investment bank JPMorgan Chase (NYSE:JPM), over the last 20 years, the FDA has only approved an average of between 20 and 25 new drugs per year. Most of those approvals have come from advanced drugs, new cancer fighters and a hefty dose of biologics.With the need to fill pipelines and replace aging blockbusters, the major biotech stocks are in a bind. And that means buying their way out of these issues. * The Top 15 Stocks to Buy in 2020 For investors, this poises an interesting scenario. Plenty of gains can be had betting on the right biotech stock with a promising pipeline as the bigger fish start spending their cash. However, which biotech stocks have the promise?Here are three biotech stocks that make for great buyout targets. Biotech Stocks That Are Buyout Targets: Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock It's no secret that gene therapy has quickly become all the rage, with pharmaceutical firms trying to tackle rare and orphan diseases. And while there are a ton of new technologies that fall under this umbrella, RNA interference (RNAi) has the potential to be a real game changer.Basically, it's a mechanism that uses a "gene's own DNA sequence of gene to turn it off." With Novartis spending nearly $10 billion on RNAi buyouts in recent months, Arrowhead Pharmaceuticals (NASDAQ:ARWR) could be an intriguing stock to look at it.ARWR's sole specialty is RNAi drugs and features a big pipeline of therapies in various stages of development. These drugs include tackling aliments like liver disease, Cystic Fibrosis and cancerous tumors. So far, the biotech has been pretty successful at navigating the various phases of clinical trials. Data from many of its late-stage drugs seem very promising.However, the real reason to be excited that ARWR could be bought out is that it already counts a very deep-pocketed biotech among its development partners. Arrowhead has already cut deals with Johnson & Johnson (NYSE:JNJ) for development of treatment for chronic hepatitis B infections. The deal provides ARWR with plenty of upfront cash, development and milestone rights. However, given the rush to buyout RNAi providers, JNJ has every reason to consider snagging the firm outright.Now, Arrowhead isn't unknown at this point. In fact, the stock has surged over the last year -- especially since October. Some of that was do to the NVS buyouts in the sector. But, a lot of it was do to ARWR's own wins and progress. But, with plenty of potential and market cap of just $6 billion, Arrowhead could provide more gains in the year ahead -- buyout or not. Amarin (AMRN)Source: Shutterstock A lot has been written about Amarin (NASDAQ:AMRN). The biotech stock has been a roller coaster the last few years, going from obscurity to being on hot lists. The reason comes down to its only medicine -Vascepa.Vascepa is really just a fish oil pill. But man, is it good. Data for the drug was stellar, with patients experiencing a 20% less chance of cardiovascular death, 31% less heart attacks and 28% less strokes. All in all, Vascepa was able to reduce cardiovascular risk by 25%. With its big cache of data and FDA approval, AMRN now has a blockbuster on its hands. Patients facing cardiovascular events who are already on statins now have another line of defense to fight. With that, AMRN now predicts that it'll be able to accumulate $650 to $700 million in sales this year.So, why buyout potential? That's an easy source of bolt-on revenue with some decent growth prospects.Cardiovascular disease remains a huge threat that only continues to get worse as diet and genetics play an increasing role. Vascepa has the potential to be the next Lipitor in that fight. And that blockbuster potential makes it a great add-on for drug companies with big cardiovascular portfolios. With a market cap of only $7 billion, Amarin is a pretty easy pill to swallow for a larger biotech stock looking to boost its sagging growth potential. * 3 Oil Stocks That Are Worth Looking Into Now In the end, Vascepa could be a blockbuster and that could lead to a sale of ARMN stock. Intercept Pharmaceuticals (ICPT)Source: Shutterstock Non-alcoholic SteatoHepatitis (NASH) remains a tough nut to crack. The progressive liver disease can destroy the organ, and is projected to become the leading cause of all liver transplants this year. For nations with fatty diets, prevalence of NASH is estimated to be as much as 20% of the total population. The problem is that most potential treatments for the disease have fallen flat.And, that could make Intercept Pharmaceuticals (NASDAQ:ICPT) the only boat in the sea.Intercept's drug Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC). PBC is very similar to NASH. This allowed ICPT to pivot the medicine and results were pretty great. So great, that ICPT recently submitted the drug for review with the FDA.Perhaps even better is that the agency granted Intercept priority review for the drug. That could lead to quicker approval time and reduce the headaches ICPT needs to get the therapy out to market.Given the potential size of NASH and the need for the drug, ICPT could be looking at a major blockbuster on it hands. And as the only man standing in the sector, that could lead to plenty of buyout activity for the stock. This is especially true as shares of the firm have slipped over the last year, but gained traction in October. With a market cap of about $4 billion, Intercept is a very digestible for many other biotech stocks.In the end, ICPT is sitting right in the sweet spot for mergers and acquisitions activity. With strong growth potential, first-mover status and a low market cap all being factors. At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 15 Stocks to Buy in 2020 * The 7 Most Important Companies That Didn't Survive the 2010s * 4 Mega-Tech Stocks Reaching for the Sky The post 3 Biotech Stocks to Bank on for Buyouts in 2020 appeared first on InvestorPlace.
Eli Lilly said it is buying a small biotech firm called Dermira in a $1.1 billion all-cash deal that would give it a promising drug for atopic dermatitis that is in Phase 3 clinical trials.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
The Zacks Analyst Blog Highlights: JPMorgan, Sanofi, General Electric, American Electric Power and Shopify
Eli Lilly and Novo Nordisk are separately offering help to people who are struggling to pay for their insulin, in a move that underscores how differently drugmakers are approaching the highly politicized topic of insulin prices.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) ...
The stock was static in 2019, but a Wall Street veteran thinks investors are overlooking the company's outstanding pipeline and strong upward momentum Continue reading...
J.P. Morgan’s Richard Vosser upgraded (SAN)(ticker: SAN.France) to Overweight from Neutral, and named (ROG)(ROG.Switzerland), (NOVO-B)(NOVOB.Copenhagen), and (AZN)(AZN) as top picks. As for Galapagos, Vosser downgraded the stock to Neutral after its blockbuster 2019.
Drugmakers including Pfizer Inc , GlaxoSmithKline PLC and Sanofi SA are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the price increases will be below 10%, and around half of them are in the range of 4 to 6%, said 3 Axis co-founder Eric Pachman. More price increases are expected to be announced later this week, which could affect the median and range.
Jan.13 -- Sanofi Chief Financial Officer Jean-Baptiste Chasseloup de Chatillon discusses the drugmaker's growth strategy, share valuation versus its peers, and cost-cutting efforts on "Bloomberg Markets: European Close."